1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
IDT Corporation's Board of Directors declared a quarterly cash dividend of $0.07 per share on September 22, 2026. The dividend is payable to stockholders of record as of October 5, 2026, providing a routine cash return to shareholders.
Quarterly cash dividend of $0.07 per share declared September 22, 2026
Nutriband announced that its publicly traded warrants (Nasdaq: NTRBW) will expire automatically under their original terms at 5:00 p.m. Eastern Time on September 30, 2026, and will be delisted after trading ends that day. The company said the expiration has no impact on its common stock, which will continue to trade on Nasdaq as NTRB, and that unexercised warrants will become void.
Warrants (NTRBW) expire at 5:00 p.m. Eastern Time on September 30, 2026
Warrant trading ceases at market close on September 30, 2026, then warrants are removed from Nasdaq listing
Expiration requires no action from warrant holders; common stock (NTRB) is unaffected
FG Nexus Inc. entered into a subscription agreement on September 17, 2026, to buy 1,818,182 shares of common stock of FG Communities, Inc. (FGC) for $10,000,001 in cash, and the purchase closed on September 21, 2026. Several FG Nexus officers and directors, including Chairman and CEO Kyle Cerminara, also hold equity in and serve as officers and directors of FGC, so the board relied on review by an independent special committee and an independent financial advisor.
Purchase of 1,818,182 FGC shares at $5.50 per share, for an aggregate $10,000,001 paid in cash
Agreement dated September 17, 2026; closing occurred September 21, 2026
Kyle Cerminara is Chairman and CEO of FG Nexus and President and Chairman of FGC
Approved by the board after review and recommendation by a special committee of independent directors and an independent financial advisor
Xenetic Biosciences furnished an updated September 2026 investor presentation tied to its pending share exchange with Santersus AG, first announced September 16, 2026. The presentation shows Santersus shareholders expected to own about 85% of the combined company and Xenetic stockholders about 15%, subject to adjustment, with closing expected in the fourth quarter of 2026.
Transaction valuation shown as $120 million for Santersus and $21 million for Xenetic, or $141 million in total, under the Share Exchange Agreement dated September 14, 2026
Closing is expected in the fourth quarter of 2026 and is subject to approval by Xenetic stockholders
The combined company is expected to trade on Nasdaq under the ticker SNTS
On September 22, 2026, Independence Realty Trust (IRT) and related parties signed an amendment to the merger agreement with Centerspace first signed on September 8, 2026. IRT elected an alternative structure for the Company Merger, under which Centerspace would merge into an IRT subsidiary that survives the merger. The filing does not state a deal value or change in consideration, so the amendment's effect on shareholder payments cannot be determined from this document.
Original Merger Agreement with Independence Realty Trust was entered into on September 8, 2026.
On September 22, 2026, IRT Merger Sub joined the agreement by joinder and IRT elected the Alternative Structure for the Company Merger only.
Under the Alternative Structure, IRT Merger Sub survives the Company Merger rather than merging into Centerspace.
The amendment includes a waiver of any representation inaccuracy caused solely by the Alternative Structure and is filed as Exhibit 2.1.
On September 23, 2026, Greenland Mines agreed to sell 1,765,420 common shares and pre-funded warrants for up to 1,434,580 shares to institutional investors at $12.00 per share or warrant, for a total of up to 3,200,000 shares. Net proceeds are expected to be about $38.4 million, to be used with existing cash for Greenland mining operations, general corporate uses and working capital, with closing expected on or about September 24, 2026. The sale adds new shares that will dilute existing holders.
Offering of 1,765,420 common shares plus pre-funded warrants for up to 1,434,580 shares, priced at $12.00 each
Expected net proceeds of about $38.4 million, after estimated offering expenses
Expected closing on or about September 24, 2026, subject to customary conditions
On September 21, 2026, private warrants were amended to a post-reverse-split exercise price of $5.00 per share
Stoneridge appointed Uwe Brandenburg as Global Vice President, Engineering & Innovation, effective November 2, 2026, under an employment agreement dated September 17, 2026. He will report to CEO Natalia Noblet and lead the company's global engineering organization, and he will serve on the Executive Team.
Annual base salary of €320,000 (about $367,168), with a target bonus of 50% of base salary
One-time special equity grant of $150,000 in time-based Stoneridge shares, vesting ratably over three years
Previously Chief Technology Officer and Senior Vice President, Automotive and Manufacturing at DXC Technology (formerly Luxoft)
IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings, completed a $2 billion offering of 6.375% senior notes maturing March 15, 2034. Proceeds will redeem the issuer's 5.000% notes due 2026, repay part of its revolving credit facility and cover offering fees. The deal refinances existing debt and adds new long-term borrowing, which shareholders may weigh against the company's debt load.
Gross proceeds of $2,000,000,000 from 6.375% senior unsecured notes due March 15, 2034
Proceeds to redeem in full the Senior 5.000% Notes due 2026 and repay part of the revolving credit facility
Interest payable semi-annually on March 15 and September 15, starting March 15, 2027
Issuer may redeem before September 15, 2029 subject to a make-whole premium
Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.
1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.
On September 22, 2026, Independence Realty Trust entered into an amendment to its merger agreement with Centerspace, under which IRT elected an alternative structure for the Company Merger, with Centerspace surviving as a wholly owned subsidiary of IRT. The amendment also includes IRT's waiver of any representation inaccuracy caused solely by the structure change, and the filing does not state any change to the consideration or deal value.
Original Merger Agreement dated September 8, 2026 was amended on September 22, 2026.
IRT Merger Sub was added to the agreement by joinder, and IRT elected the Alternative Structure for the Company Merger only.
Under the change, CSR merges with and into IRT Merger Sub, with IRT Merger Sub surviving.
The transaction remains subject to S-4 and joint proxy filings and votes of CSR and IRT shareholders.
Plug Power said Chief Operating Officer Dean C. Fullerton will resign effective October 23, 2026, to accept a position at another company, having notified the company on September 17, 2026. The filing says the resignation was not due to any disagreement with the company on its operations, policies or practices, and that his duties will move to certain Executive Vice Presidents and Vice Presidents, with Fullerton assisting the transition.
Dean C. Fullerton, Chief Operating Officer, notified the company on September 17, 2026 of his resignation
Resignation takes effect October 23, 2026
Filing states no disagreement with the company on operations, policies or practices
Duties will transfer to certain Executive Vice Presidents and Vice Presidents
TransUnion said Chief Financial Officer Todd Cello will resign effective December 31, 2026, after 29 years with the company, including nine years as CFO. He will serve as a full-time advisor through March 1, 2027, and the company has begun a search for a successor, with an interim CFO expected if no replacement is hired by the transition date. TransUnion also reaffirmed its third quarter and full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted Earnings Per Share, and said the departure is not expected to affect operations or long-term financial targets.
Todd Cello resigns as EVP and CFO effective December 31, 2026; he is not leaving over a disagreement with the company
Cello provides transition services through March 1, 2027; the company's search for a successor is underway
Transition agreement dated September 23, 2026 includes salary through March 1, 2027 and a 2026 annual bonus, subject to performance and employment through the transition date, plus COBRA coverage of up to 18 months and outplacement services
TransUnion reaffirmed third quarter and full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS
NexMetals reported assay results from drill hole SMD-26-219 at its Selebi Main deposit in Botswana, which returned 7.55 metres grading 6.48% CuEq (2.70% Cu, 1.83% Ni). A visual intercept in hole SMD-26-217 extended the High-Grade Trend by about 100 metres to approximately 1.5 kilometres and showed a third mineralized zone, with assays still pending. The release contains no financial results, and the company said the 2026 Mineral Resource Estimate remains on track for the third quarter of 2026, excluding holes drilled after the September 21 cut-off, including SMD-26-217.
SMD-26-219 returned 7.55 metres grading 6.48% CuEq in the Lower Zone, between 1,909.20 and 1,916.75 metres.
SMD-26-217 extended the High-Grade Trend by about 100 metres and intersected a combined 38.65 metres of mineralization across three zones; assays are pending.
The 2026 Mineral Resource Estimate remains on track for completion in the third quarter of 2026; holes drilled after September 21, including SMD-26-217, are excluded.
At its September 18, 2026 virtual annual meeting, OneMedNet stockholders elected three Class III directors, ratified WithumSmith+Brown as auditor for 2026, and approved a 1,000,000-share increase to the 2022 Equity Incentive Plan. They also approved a charter amendment allowing a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be set by the board.
Stockholders approved adding 1,000,000 shares to the Amended and Restated 2022 Equity Incentive Plan, effective immediately.
Proposal 4 approved a reverse split ratio from 1-for-5 to 1-for-20, with the final ratio left to the Board of Directors; 41,068,200 votes were cast for it.
Dr. Kenneth Alleyne, Sherry Coonse McCraw and Dr. Jeffrey Yu were elected as Class III directors for terms expiring at the 2029 annual meeting.
Votes represented 70.57% of eligible votes, which met the quorum requirement.
Sun Communities closed the sale of its UK business, Park Holidays, to Panther Bidco Limited, an affiliate of Aermont Capital, on September 22, 2026. The company received net cash proceeds of approximately $1.03 billion and says it expects to use them primarily for share repurchases, debt repayment and general corporate purposes. The company previously recorded a $1.1 billion valuation allowance charge on the UK business in the second quarter of 2026, and it will update its full-year 2026 outlook on its third quarter earnings call.
Closed on September 22, 2026; buyer Panther Bidco Limited is an affiliate of Aermont Capital
Net cash proceeds of approximately $1.03 billion after closing and transaction costs
Valuation allowance charge of $1.1 billion recorded in the three months ended June 30, 2026
Year-to-date through September 21, 2026, the company repurchased about 3.5 million shares for about $425 million
Wells Fargo said on September 23, 2026 that Scott E. Powell will become its Chief Risk Officer effective January 15, 2027. After that date he will no longer serve as the company's Chief Operating Officer. The filing does not describe the reasons for the change or any compensation terms.
Scott E. Powell appointed Chief Risk Officer, effective January 15, 2027
Powell will no longer serve as Chief Operating Officer after that date
Announced September 23, 2026 in an SEC Form 8-K under Item 5.02
QuidelOrtho entered into Amendment No. 1 to its credit agreement dated August 21, 2025, with Bank of America as administrative agent. The amendment resets the maximum leverage and minimum interest coverage covenant levels through the fiscal quarter ending September 30, 2029, and sets new pricing and commitment fees during that period. The filing describes added restrictions on the financial covenants, so shareholders gain covenant room but face tighter terms in the interim.
Amendment dated September 23, 2026 to the credit agreement originally dated August 21, 2025
Maximum Consolidated Leverage Ratio set at 5.50 to 1.00 for quarters through July 2, 2028, stepping down to 4.25 to 1.00 on or after September 30, 2029
Minimum Consolidated Interest Coverage Ratio set at 2.25 to 1.00, rising to 3.00 to 1.00 on or after September 30, 2029
Initial Term SOFR margin of 2.50% per annum for the Term Loan A facilities and revolver until the compliance certificate for the quarter ending September 28, 2026 is received; term loan B interest unchanged
Flotek Industries entered into a Credit Agreement on September 23, 2026, with initial term loans of $75.0 million, secured by substantially all company and subsidiary guarantor assets. The loan refinanced the $40 million PWRTEK Note, which had been guaranteed by Flotek, and matures September 23, 2031. Part of the lender group is an affiliate of ProFrac's founders, a related party, and the Audit Committee approved the transaction.
Initial term loans of $75.0 million, with up to $15.0 million more delayed-draw available through June 30, 2027 and up to $30.0 million more subject to Required Lender consent through March 31, 2028
Interest at Term SOFR with a 2.50% floor plus a 6.50% margin; maturity September 23, 2031
PC Energy Credit I LLC, an affiliate of ProFrac's founders, exchanged $12.5 million of PWRTEK Note obligations for initial term loans
Asset-based loan with Amerisource extended to October 31, 2027, with the PWRTEK Note terminated and its liens released
Five Below's board increased its size from nine to ten directors and elected Scott Settersten, former Chief Financial Officer of Ulta Beauty, effective September 21, 2026, with a seat on the Audit Committee. The filing says the board considers him independent, and he received an initial grant of 545 restricted stock units that vests at the next annual shareholder meeting.
Scott Settersten elected September 21, 2026; board expanded from nine to ten directors
Served as CFO of Ulta Beauty from 2012 until retiring in March 2024; previously 15 years at PricewaterhouseCoopers LLP
Initial grant of 545 restricted stock units; term runs until the 2027 annual shareholder meeting
Alcoa's subsidiaries completed a $2.6 billion private sale of senior notes due 2034 and 2036, with proceeds and cash on hand intended to fund the approximately $3.1 billion cash portion of the proposed South32 bauxite, alumina and aluminum smelter acquisition. The notes must be redeemed at 100% of principal plus accrued interest if the acquisition is not completed by the Special Mandatory Redemption End Date, which is at least June 29, 2027, and the company terminated its 364-day bridge loan commitments for the deal.
$1.5 billion of 6.625% senior notes due 2034 issued by Alumina Pty Ltd and $1.1 billion of 6.875% senior notes due 2036 issued by Alcoa Nederland Holding B.V.
Proceeds plus cash on hand are intended to fund the approximately $3.1 billion cash portion of the South32 acquisition and related fees and expenses.
If the acquisition is not completed by June 29, 2027, or a later date under the Deed, the notes must be redeemed at 100% of principal plus accrued interest.
Concurrently with the notes closing, Alcoa terminated all remaining commitments under its 364-day senior unsecured bridge term loan facility.
ONE Nuclear Energy LLC and Hennessy Capital Investment Corp. VII closed their business combination on September 23, 2026, and the combined company was renamed ONE Nuclear Energy Inc. Its common stock is expected to begin trading on Nasdaq under the ticker ONEN on or about September 24, 2026. Holders of 13,809,029 SPAC shares redeemed them for about $146.5 million, leaving about $2.2 million in the trust account before expenses, which the company says is intended to provide capital access for its 5 GW Louisiana Portfolio.
Holders of 13,809,029 Class A ordinary shares redeemed them at about $10.61 per share, for about $146.5 million in total
About $2.2 million remained in the Hennessy VII trust account after redemptions and forward purchase prepayments, before paying expenses
Nasdaq trading under ONEN expected on or about September 24, 2026
Portfolio includes Project Amberjack (up to 1 GW SMR), Project Cayman (2.88 GW gas plant) and Project Barracuda (1.2 GW gas plant)
SCWorx received a Nasdaq Hearings Panel decision to delist its common stock, which has been suspended from Nasdaq since April 14, 2026, and now trades on the OTCQB. The company says a September 16, 2026 private placement cured its publicly held shares deficiency and has asked the Panel to reconsider, but the Panel has not yet acted, and the outcome is uncertain for shareholders.
Nasdaq Hearings Panel decided on September 17, 2026 to delist the common stock; the company requested reconsideration on September 18, 2026.
The company says the private placement and related share issuances give it more than 500,000 publicly held shares, meeting the Publicly Held Shares Rule.
To regain Bid Price Rule compliance, the stock must close at or above $1.00 for 10 consecutive trading days on or before October 5, 2026.
If all purchasers terminate, the company would return an aggregate of $938,000 and cancel 350,000 shares and warrants; the deadline for termination notices is October 15, 2026.
Cayson Acquisition Corp shareholders approved at an extraordinary general meeting on September 23, 2026 an amendment letting the board extend the company's deadline to complete a business combination monthly, up to 12 months, to September 23, 2027. Holders of 1,428,025 public shares redeemed them for a pro rata share of the trust account, and the company's CEO loaned $60,000 to fund the trust deposit for the extension, which the filing says is repayable only upon a business combination.
Extension proposal approved with 2,858,762 votes for and 1,357,803 against
Holders of 1,428,025 public shares exercised redemption rights
CEO Yawei Cao loaned $60,000 to the company, deposited into the trust account, with no interest
Company states it continues to seek an initial business combination
Myseum.AI said on September 23, 2026 that it intends to apply to tokenize its Nasdaq-listed common stock through one or more qualified digital-asset securities platforms. The company says tokenized shares would represent its actual registered common stock and preserve shareholder rights, and that existing shareholders need take no action, but the filing states there is no assurance the application will be accepted or that tokenized trading will become available.
Announced September 23, 2026 that it intends to apply to tokenize its common stock
Tokenized shares would be designed to represent actual registered common stock, not synthetic exposure, and preserve economic and voting rights
Common stock will continue to trade on the Nasdaq Capital Market under the symbol MYSE; no shareholder action is required
Filing states there can be no assurance the application will be accepted or that tokenized trading will become available
Unity Bancorp said CEO James A. Hughes will retire effective March 31, 2027, and President George Boyan will become CEO effective April 1, 2027, under a planned succession process. Hughes will remain on the boards of the Company and Unity Bank. The company also amended Hughes' retirement plan, raising his benefit percentage from 60% to 65%, which will produce a one-time pre-tax expense of $769 thousand in the quarter ending September 30, 2026.
James A. Hughes retires as CEO effective March 31, 2027, and will continue as a director of the Company and Unity Bank
George Boyan, President since January 1, 2026, becomes CEO effective April 1, 2027
SERP amendment raises Hughes' retirement benefit from 60% to 65% of the compensation measure, with a one-time pre-tax expense of $769 thousand in the quarter ending September 30, 2026
Range Capital Acquisition Corp. disclosed that on September 22, 2026, it drew $60,000 from an unsecured, non-interest-bearing promissory note issued to its sponsor and deposited the funds into its trust account. Total outstanding under the note is now $240,000, and the note is repayable only on completion of an initial business combination or the effective winding up of the company, with repayment outside the trust if no combination occurs.
Drawdown of $60,000 on September 22, 2026, deposited into the Trust Account
Aggregate outstanding balance under the note is $240,000
Note issued June 18, 2026, up to $540,000 principal, to sponsor Range Capital Acquisition Sponsor, LLC
Note is non-interest-bearing; sponsor contributions of up to $60,000 per month
FMC closed the sale of 30,319,166 common shares to Tessenderlo Group NV at $13.30 per share, for an aggregate purchase price of $403,244,907.80, on September 23, 2026. Tessenderlo now owns approximately 20.0% of FMC's outstanding shares and gains a board nomination right, a board observer seat and preemptive rights. The filing also sets a 36-month lock-up and standstill limits, which shape how much influence and share-count dilution existing shareholders may face.
Tessenderlo bought 30,319,166 shares at $13.30 per share, for $403,244,907.80 in total.
Tessenderlo owns approximately 20.0% of FMC's outstanding common stock after the closing.
The Investor Agreement lets Tessenderlo nominate an independent director; Luc Tack, Tessenderlo's chief executive, has been nominated.
Tessenderlo is subject to a 36-month lock-up and customary standstill restrictions while it holds FMC shares.
On September 21, 2026, Bath & Body Works' compensation committee granted CEO Daniel Heaf a performance stock unit award with a target value of $10 million, equal to 591,366 shares. The award vests only if the average closing stock price over any 60 consecutive trading days reaches $40, $60, $80 or $100 during a four-year performance period, tying a large part of his pay to share price gains.
Target value of $10 million, equal to 591,366 shares of common stock, granted September 21, 2026 to CEO Daniel Heaf
Payout ranges from 75% to 200% of target at stock price goals of $40, $60, $80 and $100 over a four-year performance period
Earned units vest on the fourth anniversary of the grant date, generally subject to continued employment; earned amount is halved if total shareholder return ranks below the 55th percentile of the S&P 1500 Consumer Discretionary Distributio
Teamshares closed the sale of 225,000 shares of a new non-voting, non-convertible Series A Preferred Stock on September 23, 2026, at $990 per share, for an aggregate $222.75 million. The buyers are affiliates of a holder of more than 10% of the common stock, and the company says the proceeds are primarily intended to fund acquisitions. The preferred ranks ahead of common stock on dividends and liquidation, carries a 16.0% cash dividend rate, and includes covenants that restrict debt and require at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid.
225,000 Series A shares sold at $990 per share, or $222.75 million in aggregate, closed September 23, 2026
Liquidation preference of $1,000 per share; cumulative dividends of 16.0% per year if paid in cash or 18.0% if paid in kind
Ranks senior to common stock; non-voting and not convertible into common stock
Company may sell up to $75 million more of the same series; must keep at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid
Solaris Energy Infrastructure's subsidiary agreed on September 22, 2026 to sell $1.25 billion of 7.000% senior notes maturing April 1, 2032, in a private placement to initial purchasers led by MUFG Securities Americas. The offering was upsized from an original $1.0 billion, and the company expects about $1,227.2 million in net proceeds for general corporate purposes, growth capital expenditures and offering fees, with closing expected October 1, 2026.
Principal amount: $1.25 billion of 7.000% senior notes due April 1, 2032, issued at par, upsized from $1.0 billion
Expected net proceeds: approximately $1,227.2 million after the initial purchasers' discount and estimated offering expenses
Expected closing: October 1, 2026, subject to customary closing conditions
Use of proceeds: general corporate purposes, growth capital expenditures and offering fees and expenses
Orange County Bancorp furnished a September 2026 investor presentation as Exhibit 99.1 to a Form 8-K, to be reviewed with analysts and institutional investors at the Stephens Bank Forum 2026 on September 24, 2026. The deck covers second-quarter 2026 results, showing net income of $24.9 million and basic and diluted EPS of $1.87 for the six months ended June 30, 2026, and the filing states the material is not a determination that it is material or complete.
Presentation furnished as Exhibit 99.1 and to be reviewed at the Stephens Bank Forum 2026 on September 24, 2026
Six months ended June 30, 2026: net income of $24.9 million and basic and diluted EPS of $1.87
As of June 30, 2026: total assets of $2.8 billion, total deposits of $2.4 billion and total net loans of $1.9 billion
NeoVolta reported fiscal 2026 results for the year ended June 30, 2026, with revenue up 58% to $13.3 million but a GAAP net loss of $21.5 million, or $(0.55) per share, versus $5.0 million in fiscal 2025. Fourth-quarter revenue fell sharply to approximately $13.5 thousand, and the company attributed the decline to federal tax law changes affecting residential and installer-channel sales, which matters to shareholders because losses widened as sales in that channel dropped.
Fiscal 2026 revenue was $13.3 million, up from $8.4 million in fiscal 2025.
Fourth-quarter GAAP net loss was $11.7 million, compared with $1.6 million a year earlier, including a $3.9 million provision for credit losses and bad debt expenses.
Cash and cash equivalents were $22.2 million at June 30, 2026, plus $3.2 million of restricted cash, following a May 2026 public offering.
The company reported adjusted EBITDA of $(12.8) million for fiscal 2026, its first period disclosing this non-GAAP measure, and a senior secured term loan provides $20 million in initial funding.
Jazz Pharmaceuticals' subsidiary Jazz Financing Lux entered into Amendment No. 4 to its credit agreement on September 23, 2026, extending the maturity of the $1.9 billion Tranche B-2 dollar term loan from May 5, 2028 to May 5, 2033 and lowering its interest margin. The filing does not include new earnings, guidance, or changes to operations, so the effect on shareholders depends on the lower borrowing cost and longer repayment schedule.
Maturity extended from May 5, 2028 to May 5, 2033 for the Tranche B-3 dollar term loans
Applicable margin cut 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, with a 0.50% Term SOFR floor
Principal outstanding of $1,895,000,000 before and after the amendment; Jazz Lux also borrowed $273,310,355.18 in additional term loans to repay non-converted loans
Quarterly amortization of 0.25% of initial principal, with the remaining balance due May 5, 2033
HealthStream's Compensation Committee approved special grants of time-based and performance-based restricted share units to its named executive officers on September 18, 2026, under its shareholder-approved 2022 Omnibus Incentive Plan. The grants are meant to encourage future performance and retention, and they add to the equity compensation of these officers.
Four named executive officers (Robert A. Frist, Jr., Michael M. Collier, Trisha L. Coady, Kevin P. O'Hara) each received 15,395 time-based RSUs with a grant date fair value of $450,000, plus 5,132 performance-based RSUs valued at $150,000 e
Scott A. Roberts received 12,316 time-based RSUs valued at $360,000 and 4,105 performance-based RSUs valued at $120,000.
Time-based RSUs vest in equal annual 25% installments over four years from the grant date.
Performance-based RSUs vest in 25% increments tied to annual targets for 2027 through 2030, to be set by the Committee.
Covista Inc. entered into Amendment No. 6 to its credit agreement on September 18, 2026, repricing all $510 million of outstanding term loans. The Term SOFR margin falls from 2.25% to 2.00%, and the base rate margin falls from 1.25% to 1.00%, which lowers the interest rate on the loans. The filing states that the other terms of the credit agreement were not materially changed.
Amendment No. 6, dated September 18, 2026, repriced all $510 million of term loans, with Morgan Stanley Senior Funding, Inc. as administrative agent.
Term SOFR margin reduced from 2.25% to 2.00%; base rate margin reduced from 1.25% to 1.00%.
A 1.00% soft call applies to certain repricings or prepayments occurring within six months after the September 18, 2026 effective date.
Other material terms are unchanged; the full amended agreement is filed as Exhibit 10.1.
Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.
Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.
Arcturus said ARCT-810 was generally safe and well tolerated in an interim Phase 2 study in OTC deficiency, with reduced or maintained ammonia and reduced glutamine. The company also introduced its LUNAR 2.0 delivery platform, plans to add ARCT-2601 to the Phase 2 study near year-end, and entered a definitive agreement to acquire AI discovery company myNEO. The filing gives no financial figures, so the effect on shareholders is not quantified.
ARCT-810 reduced and/or maintained first morning fasting ammonia within the normal range; participants at the 0.5 mg/kg dose achieved mean glutamine values within the normal range during treatment
Weight gain was observed in all participants
Arcturus plans to begin dosing ARCT-2601 near year-end 2026 in OTCD patients aged 12 and older under an amended Phase 2 protocol
Acquisition of myNEO is subject to customary closing conditions and is expected to close in October 2026
Galaxy Digital said its Chief Accounting Officer, Robert Rico, will resign effective September 30, 2026, to pursue an outside opportunity. The board appointed Dritan Muneka, the company's Head of Accounting Policy since May 2022, as principal accounting officer with the title Corporate Controller, effective on the same date. The change is an orderly internal succession in a key finance role, and the filing reports no financial figures.
Robert Rico resigns as Chief Accounting Officer and principal accounting officer effective September 30, 2026; he notified the company on August 5, 2026
Board appointed Dritan Muneka on September 22, 2026, as principal accounting officer with the title Corporate Controller
Muneka previously worked at KPMG LLP from November 2010 to April 2022, ending as Managing Director, and is a certified public accountant
Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026, and issued $350 million of senior secured notes to fund part of the cash consideration and contingent value rights payments. The filing also sets out contingent value rights (CVRs) that give holders a share of certain future license proceeds, a $50 million milestone payment and a share of net sales, with the filing stating that payment is uncertain.
Notes carry a fixed 8.25% interest rate and mature December 31, 2036, with quarterly interest payments beginning December 2026.
The notes are guaranteed by Zymeworks subsidiaries and secured by a first-priority lien on substantially all of the issuers' and guarantors' personal property, subject to customary exclusions.
CVR holders may receive 80% of net license proceeds within 10 years, a $50 million milestone payment on first commercial sale of ampreloxetine in specified markets, and 10% of net sales; the filing calls these payments highly speculative.
Zymeworks will hold a conference call on Monday, September 28, 2026, at 8:30 a.m. Eastern Time.
Gossamer Bio said it submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension, its first NDA. The application relies on the Phase 3 PROSERA study as one adequate and well-controlled investigation, supported by the Phase 2 TORREY study. The FDA has not yet decided whether to accept the application for filing, which the company expects could happen later this year.
NDA for seralutinib in PAH submitted to the FDA in September 2026, the company's first NDA
Submission follows a Pre-NDA Type B meeting with the FDA in June 2026 and the FDA's written meeting minutes
FDA will decide whether to accept the NDA for filing after its initial review, which the company anticipates could occur later this year
AtlasClear Holdings preliminarily reported fiscal 2026 revenue (year ended June 30, 2026) of about $20.1 million, up about 85% from $10.9 million, and about $21.9 million including interest income. It also expects net income of about $2.0 million, its second straight year of positive net income, though these preliminary, unaudited results may change once the audit is complete.
Total revenues of about $20.1 million, up about 85% from $10.9 million; with $1.8 million of interest income, about $21.9 million, versus $12.9 million in fiscal 2025.
Stock locate fees rose to about $6.8 million from $0.3 million; commission revenue grew about 56% to about $9.3 million.
Expected net income of about $2.0 million, including non-cash fair value gains; cash about $15.4 million and stockholders' equity about $21.1 million at June 30, 2026, versus a $6.8 million deficit a year earlier.
Results are unaudited and may differ materially; the company expects to file its 10-K and report full results by September 28, 2026.
Mobile Infrastructure Corporation signed a Fifth Amendment to its Credit Agreement on September 22, 2026, with Harvest Small Cap Partners entities, extending the maturity date from September 30, 2026 to December 31, 2026. The filing describes the amendment as a related party transaction because co-chair Jeffrey Osher is managing member of the lenders' investment manager; the filing does not state the loan amount. The same day, the board declared monthly preferred stock dividends payable on or about October 12, 2026.
Credit Agreement maturity extended from September 30, 2026 to December 31, 2026 under the Fifth Amendment dated September 22, 2026.
Lenders are Harvest Small Cap Partners, L.P. and Harvest Small Cap Partners Master, Ltd.; co-chair Jeffrey Osher is managing member of No Street Capital LLC, their investment manager.
Series A Preferred Stock dividend of $4.791 per share and Series 1 Preferred Stock dividend of $4.583 per share, payable on or about October 12, 2026.
Record dates: September 27, 2026 for Series A Preferred Stock and September 24, 2026 for Series 1 Preferred Stock.
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Flywire Corporation's board appointed Sabrina Farmer as a Class II director on September 22, 2026, increasing the board from nine to ten members. She also joined the Nominating and Corporate Governance Committee, and the filing describes her as independent under Nasdaq rules. The filing reports no financial results, and the board change itself does not include financial figures beyond her director pay.
Board appointed Sabrina Farmer on September 22, 2026; her initial term expires at the 2029 annual meeting.
Board size increased from nine to ten directors.
Annual cash retainer of $35,000 for board service plus $4,000 for Nominating and Corporate Governance Committee service.
Initial restricted stock unit award with a fair market value of $350,000, vesting in three equal annual installments, and an annual award of $175,000 tied to annual meetings.
Stitch Fix reported fourth quarter and full fiscal 2026 results, with revenue up 4.2% in the quarter and 6.4% for the year, and a narrower net loss than a year earlier. The company expects fiscal 2027 revenue of $1.310 billion to $1.360 billion, a decline of 2.8% to growth of 0.9%, citing a more challenging consumer environment and a lower active client base, which weighs on shareholder expectations for growth.
Q4 fiscal 2026 net revenue was $324.4 million, up 4.2% year-over-year, with a net loss of $2.1 million versus $8.6 million a year earlier.
Full fiscal 2026 net revenue was $1.35 billion, up 6.4%, with a net loss of $12.6 million versus $28.7 million; gross margin was 43.7%, down 70 basis points.
Fiscal 2027 net revenue outlook is $1.310 billion to $1.360 billion, or (2.8)% to 0.9% year-over-year; Q1 fiscal 2027 outlook is $323 million to $328 million, or (5.6)% to (4.1)%.
Active clients were 2.277 million at August 1, 2026, down 1.4% year-over-year; the company cited shipment timing and an August post-checkout offer flow change that reduced Fix volume in Q1.
Central Plains Bancshares (CPBI) disclosed that the board of its subsidiary, Home Federal Savings and Loan Association of Grand Island, extended the employment and change in control agreements for its CEO and two executive officers. The terms now expire on October 24, 2029, and the filing states no other changes were made to the agreements.
On September 22, 2026, the board extended the employment agreement with CEO Dannel R. Garness.
Change in control agreements for CFO Bradley M. Kool and Chief Lending Officer Kurt A. Haecker were also extended.
All extended agreements now expire on October 24, 2029.
The filing states there were no other changes to the agreements.
Apogee Enterprises said it completed its acquisition of GroGlass, a Latvian glass coatings business, on September 18, 2026. The deal values GroGlass at approximately €62.5 million on a cash-free, debt-free basis, plus contingent consideration of up to €10 million tied to financial targets over three years after closing.
Acquisition closed September 18, 2026, through subsidiary Tiger MergeCo SIA
Valued at approximately €62.5 million cash-free, debt-free; earnout capped at €10 million over three years
Funded with available cash and borrowings under the existing revolving credit facility
Press release puts total value at up to approximately $71.8 million at current exchange rates, including earnout
Ondas Inc. completed acquisitions of CaribouLabs, Insignito Solutions and Ottopia Technologies on September 23, 2026, for aggregate consideration of $56 million payable in cash or common stock, with up to $32 million in potential earnouts through 2028. The company also filed a prospectus covering resale by certain stockholders of 7,822,077 shares issued in the acquisitions and a prior World View acquisition, and granted inducement equity awards to 37 new employees.
Aggregate consideration of $56 million; potential earnout of up to $32 million through 2028, payable in cash or stock.
Filing covers resale of 7,822,077 shares, including 7,821,445 shares issued on September 23, 2026 for the three acquisitions and 632 shares issued April 1, 2026 for the World View Enterprises acquisition.
Inducement grants of 2,979,063 RSUs and options on 80,000 shares, at an exercise price of $7.72, were approved for 37 newly hired employees.
Greenland Technologies Holding Corporation received a Nasdaq letter on September 22, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement. The company's Class A ordinary shares closed at $1.00 or above for 10 consecutive business days from September 8 through September 21, 2026, and Nasdaq has closed the matter. For shareholders, this removes the risk of delisting over the bid price issue.
Nasdaq notified the company on March 12, 2026 that its Class A ordinary shares had closed below $1.00 for 30 consecutive business days
On September 10, 2026, Nasdaq granted an additional 180-day period, to March 8, 2027, to regain compliance
On September 22, 2026, Nasdaq confirmed compliance after 10 consecutive business days at or above $1.00, from September 8 through September 21, 2026
Pilgrim's Pride Corporation and its subsidiary Pilgrim's Europe Finance PLC completed a private sale of €500 million of 4.750% senior notes due January 23, 2034, on September 23, 2026. The company said it will use the net proceeds for general corporate purposes, including the consideration for its recently announced acquisition of Walkers Deli & Sausage Company, which adds debt that shareholders should weigh against the deal.
Principal amount: €500 million of 4.750% senior notes, issued by Pilgrim's Pride and Pilgrim's Europe Finance PLC as co-issuers
Interest is payable annually in arrears each January 23, starting January 23, 2027; notes mature January 23, 2034
Proceeds are intended for general corporate purposes, including funding the Walkers Acquisition consideration and related costs
Notes were sold to qualified institutional buyers under Rule 144A and to certain non-US persons under Regulation S; Citibank, N.A., London Branch is trustee
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.